APA
Abou-Alfa G. K., Shi Q., Knox J. J., Kaubisch A., Niedzwiecki D., Posey J., Tan B. R., Kavan P., Goel R., Lammers P. E., Bekaii-Saab T. S., Tam V. C., Rajdev L., Kelley R. K., El Dika I., Zemla T., Potaracke R. I., Balletti J., El-Khoueiry A. B., Harding J. J., Suga J. M., Schwartz L. H., Goldberg R. M., Bertagnolli M. M., Meyerhardt J., O'Reilly E. M. & Venook A. P. (2019). Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. : JAMA oncology.
Chicago
Abou-Alfa Ghassan K, Shi Qian, Knox Jennifer J, Kaubisch Andreas, Niedzwiecki Donna, Posey James, Tan Benjamin R, Kavan Petr, Goel Rakesh, Lammers Philip E, Bekaii-Saab Tanios S, Tam Vincent C, Rajdev Lakshmi, Kelley Robin K, El Dika Imane, Zemla Tyler, Potaracke Ryan I, Balletti Jennifer, El-Khoueiry Anthony B, Harding James J, Suga Jennifer M, Schwartz Lawrence H, Goldberg Richard M, Bertagnolli Monica M, Meyerhardt Jeffrey, O'Reilly Eileen M and Venook Alan P. 2019. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. : JAMA oncology.
Harvard
Abou-Alfa G. K., Shi Q., Knox J. J., Kaubisch A., Niedzwiecki D., Posey J., Tan B. R., Kavan P., Goel R., Lammers P. E., Bekaii-Saab T. S., Tam V. C., Rajdev L., Kelley R. K., El Dika I., Zemla T., Potaracke R. I., Balletti J., El-Khoueiry A. B., Harding J. J., Suga J. M., Schwartz L. H., Goldberg R. M., Bertagnolli M. M., Meyerhardt J., O'Reilly E. M. and Venook A. P. (2019). Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. : JAMA oncology.
MLA
Abou-Alfa Ghassan K, Shi Qian, Knox Jennifer J, Kaubisch Andreas, Niedzwiecki Donna, Posey James, Tan Benjamin R, Kavan Petr, Goel Rakesh, Lammers Philip E, Bekaii-Saab Tanios S, Tam Vincent C, Rajdev Lakshmi, Kelley Robin K, El Dika Imane, Zemla Tyler, Potaracke Ryan I, Balletti Jennifer, El-Khoueiry Anthony B, Harding James J, Suga Jennifer M, Schwartz Lawrence H, Goldberg Richard M, Bertagnolli Monica M, Meyerhardt Jeffrey, O'Reilly Eileen M and Venook Alan P. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. : JAMA oncology. 2019.